- Black D M, Cummings S R, Karpf D B. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348(9041)1535–41
- Black D, Schwartz A, Ensrud K, Rybak-Feiglin A, Gupta J, Lombardi A, Wallace R, Levis S, Quandt S, Satterfield S, Cauley J, Cummings S. A 5 year randomized trial of the long-term efficacy and safety of alendronate. J Bone Mineral Res (Suppl 1) 2004; 10: S45
- Currey J D. Effects of differences in mineralization on the mechanical properties of bone. Philos Trans R Soc Lond B Biol Sci 1984; 304: 509–18
- Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80–100
- Goh S-K, Yang J S B, Koh M K, Wong S Y, Chua DTC, Chua T, Howe S. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg (Br) 2007; 89(3)49–53
- Kwek E B, Goh S K, Koh J S, Png M A, Howe T S. An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy?. Injury 2008; 39(2)224–31
- Mashiba T, Turner C H, Hirano T, Forwood M R, Johnston C C, Burr D B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and bio-mechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28: 524–31
- Mashiba T, Mori S, Burr D B, Komatsubara S, Cao Y, Manabe T. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005; 23 Suppl: 36–42
- Odvina C V, Zerwekh JE, Rao D S, Maalouf N, Gottschalk F A, Pak CYC. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294–301
- Ott S. Long-term safety of bisphosphonates. Editorial. J Clin Endocrinol Metab 2005; 90: 1897–9
- Pauwels F. Die Bedeutung der Bauprinzipien des Stutz‐ und Bewegungsapparates fur die. beanspruchung der Röhren‐knochen. Anat Embryol 1948; 114: 1–2
- Tonino R P, Meunier P J, Emkey R, Rodriguez-Portales J A, Menkes C-J, Wasnich R D, Bone H G, Santora A C, Wu M, Desai R, Ross P D. Skeletal benefits of Aalendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000; 85: 3109–15
Acta Orthopaedica
Volume 79, 2008 - Issue 4